Paired tumor/germline testing is far from standard practice in cancer care, but some experts in the field are advocating that when patients have their tumors genomically profiled to determine precision medicine options, that is an opportunity to also evaluate them for their inherited risks for cancers.

Despite barriers, such as reimbursement, some labs in the field are recognizing this, and are starting to inform physicians of suspected incidental germline findings in tumor analysis.

To read the full article, click here.